FindTrial
Sign In

Population pharmacokinetics and individualized dosing of vancomycin during oXiris®-CRRT in critically Ill patients

Population pharmacokinetics and individualized dosing of vancomycin during oXiris®-CRRT in critically Ill patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600120094
Enrollment
Unknown
Registered
2026-03-09
Start date
2026-03-09
Completion date
Unknown
Last updated
2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Observation Group:none

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Critically ill patients aged = 18 years; 2. Patients diagnosed with or suspected of gram-positive bacterial infection who require vancomycin treatment; 3. Patients receiving continuous venovenous hemodiafiltration (CVVHDF) with oXiris® filters; 4. Expected duration of CRRT = 72 hours; 5. Informed consent obtained from the patient or their authorized family member.

Exclusion criteria

Exclusion criteria: 1. History of allergy to vancomycin, aminoglycosides, and glycopeptide antibiotics; 2. Pregnancy or lactation period; 3. Expected survival time 24 hours prior to the start of the study.

Design outcomes

Primary

MeasureTime frame
Vancomycin concentration;APACHE II score and SOFA score;—

Secondary

MeasureTime frame
Renal function;Survival status;—

Countries

China

Contacts

Public ContactLing Zhang

West China Hospital, Sichuan University

zhangling_crrt@163.com+86 189 8060 1985

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 20, 2026